KLAC vs. CRVS
KLAC (KLA Corporation) and CRVS (Corvus Pharmaceuticals, Inc.) are both stocks. KLAC operates in Semiconductor Equipment & Materials (Technology), while CRVS operates in Biotechnology (Healthcare). Over the past 10 years, KLAC returned 42.36%/yr vs -1.39%/yr for CRVS. At a 0.18 correlation, their price movements are largely independent.
Performance
KLAC vs. CRVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KLAC achieves a 73.94% return, which is significantly higher than CRVS's 44.81% return. Over the past 10 years, KLAC has outperformed CRVS with an annualized return of 42.36%, while CRVS has yielded a comparatively lower -1.39% annualized return.
KLAC
- 1D
- 9.27%
- 1M
- 12.92%
- YTD
- 73.94%
- 6M
- 72.59%
- 1Y
- 162.58%
- 3Y*
- 66.83%
- 5Y*
- 47.83%
- 10Y*
- 42.36%
CRVS
- 1D
- 0.27%
- 1M
- -28.30%
- YTD
- 44.81%
- 6M
- 30.26%
- 1Y
- 185.17%
- 3Y*
- 46.04%
- 5Y*
- 31.93%
- 10Y*
- -1.39%
KLAC vs. CRVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
KLAC KLA Corporation | 73.94% | 94.48% | 9.36% | 56.05% | -11.20% | 68.05% | 47.94% | 103.99% | -12.49% | 36.80% |
CRVS Corvus Pharmaceuticals, Inc. | 44.81% | 43.93% | 203.98% | 107.06% | -64.73% | -32.30% | -34.56% | 48.23% | -64.58% | -27.55% |
Correlation
The correlation between KLAC and CRVS is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Mar 24, 2016 | 0.18 |
Fundamentals
KLAC:
$278.42B
CRVS:
$1.00B
KLAC:
$35.29
CRVS:
-$0.53
KLAC:
47.75
CRVS:
4.17
KLAC:
$13.10B
CRVS:
$0.00
KLAC:
$8.09B
CRVS:
-$26.00K
KLAC:
$5.77B
CRVS:
-$47.43M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KLAC vs. CRVS — Risk / Return Rank
KLAC
CRVS
KLAC vs. CRVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for KLA Corporation (KLAC) and Corvus Pharmaceuticals, Inc. (CRVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KLAC | CRVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.40 | ||
| Sortino ratioReturn per unit of downside risk | -0.87 | ||
| Omega ratioGain probability vs. loss probability | 1.49 | 1.48 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 7.30 | 3.30 | +4.00 |
| Martin ratioReturn relative to average drawdown | 23.22 | 7.42 | +15.80 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KLAC | CRVS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.43 | 1.03 | +2.40 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 1.11 | 0.24 | +0.86 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 1.02 | -0.01 | +1.03 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.45 | -0.02 | +0.47 |
Drawdowns
KLAC vs. CRVS - Drawdown Comparison
The maximum KLAC drawdown since its inception was -83.74%, smaller than the maximum CRVS drawdown of -96.97%. Use the drawdown chart below to compare losses from any high point for KLAC and CRVS.
Loading charts...
Drawdown Indicators
| KLAC | CRVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.74% | -96.97% | +13.23% |
Max Drawdown (1Y)Largest decline over 1 year | -22.41% | -56.43% | +34.02% |
Max Drawdown (3Y)Largest decline over 3 years | -34.95% | -70.50% | +35.55% |
Max Drawdown (5Y)Largest decline over 5 years | -40.28% | -92.40% | +52.12% |
Max Drawdown (10Y)Largest decline over 10 years | -40.28% | -96.97% | +56.69% |
Current DrawdownCurrent decline from peak | -1.08% | -56.31% | +55.23% |
Average DrawdownAverage peak-to-trough decline | -29.34% | -69.32% | +39.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.03% | 25.07% | -18.04% |
Volatility
KLAC vs. CRVS - Volatility Comparison
The current volatility for KLA Corporation (KLAC) is 19.61%, while Corvus Pharmaceuticals, Inc. (CRVS) has a volatility of 23.70%. This indicates that KLAC experiences smaller price fluctuations and is considered to be less risky than CRVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KLAC | CRVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.61% | 23.70% | -4.09% |
Volatility (6M)Calculated over the trailing 6-month period | 40.06% | 111.87% | -71.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.74% | 181.10% | -133.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.46% | 131.06% | -87.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.64% | 111.16% | -69.52% |
Dividends
KLAC vs. CRVS - Dividend Comparison
KLAC's dividend yield for the trailing twelve months is around 0.38%, while CRVS has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CRVS Corvus Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
KLAC KLA Corporation | 0.38% | 0.61% | 0.96% | 0.92% | 1.25% | 0.91% | 1.35% | 1.74% | 3.17% | 2.15% | 2.67% | 2.94% |
Financials
KLAC vs. CRVS - Financials Comparison
This section allows you to compare key financial metrics between KLA Corporation and Corvus Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
KLAC and CRVS have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRVS has higher volatility (23.70%) compared to KLAC (19.61%). In terms of maximum drawdown, KLAC dropped -83.74% vs CRVS's -96.97%.
KLAC currently has the higher Sharpe Ratio (3.43 vs 1.03), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KLAC and CRVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer